EMCURE.NS Emcure Pharmaceuticals Ltd.
Price history
Price is the daily close from stored Kite history. The other metrics pair that daily price with the company's periodic filings — each fundamental (revenue, EPS, equity…) is held flat at its latest filed value between annual filings, so a ratio steps at each filing and moves daily only through its price term. A metric with no input on file for this company (e.g. EV/EBITDA for a bank, which has no EBIT) is shown as unavailable, never guessed. Share-count-based metrics use the latest diluted share count against split/bonus-adjusted prices.
Technical indicators
ℹ These reflect only the stock's recent price and volume behavior — not the company's fundamentals — and are not a recommendation to buy or sell. Standard published parameters are used throughout (see each chart's own label); a company with too little stored price history for a given indicator's lookback window shows that plainly below rather than a garbage or misleading value.
MACD (12,26,9), Stochastic Oscillator (14,3) and Money Flow Index (14-day) each carry their own published reference lines/bands (20/80 for the oscillator readings) where one is standard. ADX includes +DI/-DI for direction alongside trend strength; a dashed line marks the commonly published 25 "trending market" reading. ATR is shown in raw rupees here; the price/volume preset screen (below, and on the Screener page) reports it as a % of price so it's comparable across stocks at different price levels. Computed from the same stored daily OHLCV history as the price chart above — no new data source.
Delivery volume
| Date | Traded Qty | Delivery Qty | Delivery % |
|---|---|---|---|
| 2026-08-28 | 133174 | 81221 | 60.99% |
| 2026-08-27 | 104535 | 66171 | 63.30% |
| 2026-08-26 | 74864 | 46461 | 62.06% |
| 2026-08-25 | 77343 | 45273 | 58.54% |
| 2026-08-24 | 162164 | 80450 | 49.61% |
| 2026-08-21 | 124891 | 86722 | 69.44% |
| 2026-08-20 | 126940 | 72734 | 57.30% |
| 2026-08-19 | 124266 | 76997 | 61.96% |
| 2026-08-18 | 136782 | 82020 | 59.96% |
| 2026-08-17 | 220968 | 152944 | 69.22% |
| 2026-08-14 | 132011 | 77116 | 58.42% |
| 2026-08-13 | 54656 | 33549 | 61.38% |
| 2026-08-12 | 214106 | 149966 | 70.04% |
| 2026-08-11 | 97589 | 54451 | 55.80% |
| 2026-08-10 | 205967 | 91379 | 44.37% |
| 2026-08-07 | 145070 | 74043 | 51.04% |
| 2026-08-06 | 270432 | 78937 | 29.19% |
| 2026-08-05 | 178885 | 84896 | 47.46% |
| 2026-08-04 | 103614 | 68306 | 65.92% |
| 2026-08-03 | 116048 | 65740 | 56.65% |
Delivery quantity/percentage from the NSE bhavcopy (DELIV_QTY/DELIV_PER) — the share of that day's traded volume that actually settled into a demat account, rather than being squared off intraday. A higher delivery percentage is commonly read as genuine accumulation/distribution rather than speculative same-day trading; this describes recent trading PATTERN, not the company itself, and is not a recommendation to buy or sell. A blank cell is a day NSE itself published no figure for, never a zero. Run python manage.py refresh_delivery_volumes --tickers EMCURE.NS to fetch more history.
Insider trading activity
No insider-trading disclosures on file — run python manage.py refresh_insider_trades --tickers EMCURE.NS. (No stored disclosures may mean none have been fetched yet, or that NSE has genuinely published none for this company.)
Extract this company (financials + ratios + citations): CSV · XLSX
Full statements: Profit & Loss · Balance Sheet · Cash Flow · Compare with 46 peers in Healthcare · Trace Score
Ratios
This is cash paid during the fiscal year, not a per-share rate declared for it (no such element exists in the filing data) — timing can straddle interim/final dividends across years, and pre-FY2020-21 figures may include the since-abolished Dividend Distribution Tax, reading higher than later years for that reason alone.
Growth & earnings trend
Revenue & Profit CAGR
Operating Margin Trend
ROCE Trajectory
Earnings Quality
Needs net profit and CFO for 3+ stored years; only 2 on file.
Sector-Relative Percentile (Healthcare)
Quarterly trend
| Metric (to shareholders basis) | Q1 FY2024-25 | Q2 FY2024-25 | Q3 FY2024-25 | Q4 FY2024-25 | Q1 FY2025-26 | Q2 FY2025-26 | Q3 FY2025-26 | Q4 FY2025-26 | Q1 FY2026-27 | Source |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹1,815.14 Cr. | ₹2,001.98 Cr. | ₹1,962.63 Cr. | ₹2,116.24 Cr. | ₹2,100.54 Cr. | ₹2,269.82 Cr. | ₹2,363.48 Cr. | ₹2,469.70 Cr. | ₹2,580.45 Cr. | RevenueFromOperations |
| Net Profit | ₹144.08 Cr. incl. minority ₹152.59 Cr. | ₹194.57 Cr. incl. minority ₹201.55 Cr. | ₹153.72 Cr. incl. minority ₹156.09 Cr. | ₹188.96 Cr. incl. minority ₹197.24 Cr. | ₹206.95 Cr. incl. minority ₹214.79 Cr. | ₹243.46 Cr. incl. minority ₹251.37 Cr. | ₹230.54 Cr. incl. minority ₹231.37 Cr. | ₹243.40 Cr. incl. minority ₹243.74 Cr. | ₹293.98 Cr. incl. minority ₹292.49 Cr. | ProfitOrLossAttributableToOwnersOfParent |
Primary figures are Revenue from Operations and Net Profit attributable to shareholders — the basis the ratios use. Where they differ, the companion Gross revenue (incl. inter-segment) and incl. minority net profit (the totals a news headline usually quotes) are shown beneath, each traceable to its own XBRL element. Quarters shown are however many are actually stored (up to 10) — run python manage.py refresh_quarterly_trend --tickers EMCURE.NS to fetch more.
Source document — income statement (FY2025-26, raw filing line items)
View original filing on NSE ↗ NSE's own filing document, opened in a new tab — StockProof links to it, never stores a copy.
| ProfitOrLossAttributableToOwnersOfParent | 9243610000.0 |
| PaidUpValueOfEquityShareCapital ÷ FaceValueOfEquityShareCapital | 189590000.0 |
Source document — balance sheet (FY2025-26, raw filing line items)
View original filing on NSE ↗ NSE's own filing document, opened in a new tab — StockProof links to it, never stores a copy.
| CurrentAssets | 57090300000.0 |
| CurrentLiabilities | 39122410000.0 |
| EquityAttributableToOwnersOfParent | 49500320000.0 |
| BorrowingsCurrent + BorrowingsNoncurrent | 12040830000.0 |